Antimicrobial Susceptibility Testing Market, By Product Type (Manual Antimicrobial Susceptibility Testing Products, Automated Laboratory Instruments, and Consumables), By Application (Antibacterial, Antifungal, Anti-parasitic, and Antiviral), By Method (Disk Diffusion, Rapid Automated AST, Broth Dilution, Gradient Diffusion, and Genotypic Methods), By End User (Hospitals, Pathology/Diagnostic Laboratories, Research and Academic Institutes, Pharmaceutical and Biotechnology Companies, and Contract Research Organizations), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : May 2024

Code : CMI2449

Pages :258

Formats :

Excel and PDF

Industry : Clinical Diagnostic

Antimicrobial Susceptibility Testing Market Size and Trends

Global antimicrobial susceptibility testing market is estimated to be valued at USD 3.94 Bn in 2024 and is expected to reach USD 6.19 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 6.7% from 2024 to 2031.

Antimicrobial Susceptibility Testing Market Key Factors

To learn more about this report, request sample copy

The global antimicrobial susceptibility testing market is expected to grow steadily owing to the rising prevalence of hospital-acquired infections and increasing antibiotic resistance worldwide. Furthermore, the growing need to manage antimicrobial resistance and optimize antibiotic usage is expected to drive the demand for antimicrobial susceptibility testing products and services. Technological advancements in susceptibility testing platforms introducing automation and faster time-to-results will also support the market growth over the forecast period.

Increasing Product Launches by Key Market Players

Increasing adoption of inorganic growth strategies, such as product launches, by key market players is expected to drive the market growth over the forecast market. For instance, Sysmex Corporation, a medical technology company, announced that it had launched point-of-care testing system in Europe to detect antimicrobial susceptibility in just 30 minutes. The system detects the presence or absence of bacteria and assesses the effectiveness of antimicrobials using urine samples from patients suspected of having urinary tract infections (UTIs). Using a unique and proprietary microfluidic technology, the system delivers antimicrobial susceptibility testing (AST). It results in as little as 30 minutes from the start of measurement, a significant reduction compared to the several days required for conventional AST.

/p>Advancements in Antimicrobial Susceptibility Testing Technologies

Advancements in molecular diagnostic techniques and automation technologies are revolutionizing the field of antimicrobial susceptibility testing. Traditional AST methods based on culture and phenotypic identification are being replaced by rapid diagnostic tests that detect genetic markers of drug resistance directly from clinical samples. Technologies, such as polymerase chain reaction (PCR), DNA microarrays, mass spectrometry, and whole genome sequencing, are enabling the detection of resistance within hours instead of days. At the same time, fully automated systems for AST are reducing turnaround time and labor, improving efficiency as well as standardization of test results. This shift from conventional methods to innovative diagnostic platforms is propelling the antimicrobial susceptibility testing market growth. Diagnostic companies are continuously launching simple, user-friendly systems suitable for routine testing in core laboratories as well as point-of-care testing. The development of platforms that integrate sample-to-result workflow and provide results comparable to reference methods is enhancing the AST uptake significantly. Thus, technological evolution is a key driver as it addresses some of the limitations of existing methods improving antibiotic stewardship.